These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8128433)

  • 21. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor IX concentrates for clinical use.
    Thompson AR
    Semin Thromb Hemost; 1993; 19(1):25-36. PubMed ID: 8456321
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 26. Biochemical comparison of seven commercially available prothrombin complex concentrates.
    Kalina U; Bickhard H; Schulte S
    Int J Clin Pract; 2008 Oct; 62(10):1614-22. PubMed ID: 18691229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
    N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
    Negrier C; Vial J; Vinciguerra C; Berruyer M; Dechavanne M
    Am J Hematol; 1995 Feb; 48(2):120-4. PubMed ID: 7847325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate.
    Morfini M; Longo G; Berntorp E; Cinotti S; Filimberti E; Messori A; Nilsson IM; Rossi Ferrini P
    Thromb Res; 1993 Aug; 71(3):175-84. PubMed ID: 8211885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congenital bleeding disorders of the vitamin K-dependent clotting factors.
    Girolami A; Scandellari R; Scapin M; Vettore S
    Vitam Horm; 2008; 78():281-374. PubMed ID: 18374200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prothrombin complex concentrates.
    Penner JA
    Bibl Haematol; 1977; 44():81-7. PubMed ID: 617787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 38. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 40. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.